Hearing Characteristics of Adults before Exposure to Potentially Ototoxic Chemotherapy

Cancer patients undergoing potentially-ototoxic chemotherapy may present a series of hearing disorders and risk factors prior to treatment. Thus, it is necessary to know the profile of these patients to promote preventive actions and guidelines regarding the hearing health of these individuals....

Audiologists should ensure baseline hearing assessments (including high-frequency audiometry) are completed before ototoxic chemotherapy begins; this study reinforces existing ototoxicity monitoring guidelines and may inform risk stratification prior to treatment.

Characterising pre-treatment hearing status in oncology patients is a critical step in ototoxicity (medication-related hearing damage) monitoring programmes and helps distinguish treatment-related hearing decline from pre-existing loss.

1. 01Study profiles baseline hearing and risk factors in adult cancer patients before ototoxic chemotherapy.
2. 02Ototoxic chemotherapy (e.g., cisplatin) is a known cause of permanent hearing damage.
3. 03Baseline audiometry is essential to differentiate pre-existing hearing loss from treatment-induced loss.
4. 04Published in the International Archives of Otorhinolaryngology.
5. 05Risk factor identification pre-treatment could allow prioritisation of high-risk patients for closer monitoring.

PMID

42077937

DOI

10.1055/s-0046-1819640.

Journal

International Archives of Otorhinolaryngology

Publication type

research_article

Evidence level

4

Population

Adult cancer patients prior to exposure to potentially ototoxic chemotherapy

Intervention

Baseline audiological assessment prior to ototoxic chemotherapy